Paul S. Yamauchi, M.D., Ph.D.
Dr. Yamauchi obtained his B.S. in biochemistry at UCLA and his Ph.D. in biologic chemistry from UC Santa Barbara. After earning his medical degree from Case Western Reserve University, Dr. Yamauchi completed his residency in dermatology at UCLA. Dr. Yamauchi is the founder of Clinical Science Institute and the Dermatology Institute and Skin Care Center in Santa Monica, CA. He is board-certified in dermatology and is Clinical Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA and Adjunct Associate Professor at the John Wayne Cancer Institute.
Dr. Yamauchi has published over 50 scientific journal papers and abstracts and has written and edited several books. He is an internationally renowned speaker and frequently lectures at various professional settings, and is often quoted in the media. He has been the principal investigator in more than 100 clinical trials in various aspects of dermatology. Dr. Yamauchi’s research has entailed psoriasis, eczema, acne, rosacea, cosmetic dermatology, skin cancers, laser devices and has a special interest in cutaneous immunology and autoimmune diseases.
Dr. Yamauchi’s Recent Publications
Yamauchi PS. Soft tissue filler and botulinum toxin treatment techniques. G
Ital Dermatol Venereol. 2012 Feb;147(1):29-44.
Yamauchi PS. Selection and preference for botulinum toxins in the management of photoaging and facial lines: patient and physician considerations. Patient Prefer Adherence. 2010 Sep 7;4:345-54.
Yamauchi PS, Mau N. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dermatol. 2009 Jul;61(1):158-60.
Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol. 2009 Feb;8(2):181-3.
Gee S, Yamauchi PS. Nonsurgical management of hyperhidrosis. Thorac Surg Clin. 2008 May;18(2):141-55.
Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011 Sep;165(3):661-8.
Reinstadler A, Mau N, Bhutani T, Talkin B, Yamauchi P, Chiu M, Peng D. Perioperative use of anti-tumor necrosis factor-alfa agents. J Am Acad Dermatol. 2010 Jan;62(1):154-5.
Ortiz A, Yamauchi PS. Rapidly growing squamous cell carcinoma from permanent makeup tattoo. J Am Acad Dermatol. 2009 Jun;60(6):1073-4.
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008 Aug;159(2):322-30.
Commitment and Diligence
Our professional staff at CSI is trained to conduct clinical research with a superior level of patient care and education. The clinical trials that are conducted are performed to the highest standards. All efforts are made to ensure the trials are safe, precise, and ethical. All clinical trials are performed under the guidance of the principles of Good Clinical Practice and are under the auspices of an Institutional Review Board. CSI employs the experienced research coordinators to ensure the safety in these trials and maintain the highest level of satisfaction to our patients at our facility.
Our Research Center
CSI is part of a 4,000 square foot brand new state of the art modern medical facility located in Santa Monica, California with convenient access to freeways and public transportation. CSI is approximately 20 minutes from the Los Angeles International Airport (LAX). We are in the medical plaza adjacent to Saint John’s Health Center.